Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

of leasehold

improvements - - 1,030

Depreciation and amortization 297 321 3,115

In-process research and

development - - 418

Total operating expenses 10,232 12,448 144,638

Loss from operations (10,232) (9,288) (139,694)

Other income (expenses):

Interest income 693 1,702 9,643

Interest expense (92) (70) (1,500)

Change in fair value of

warrant liability (64) - (454)

Other expense - - (1,180)

Loss before tax benefit (9,695) (7,656) (133,185)

(Provision for)/benefit

from income taxes - (75) 620

Net loss (9,695) (7,731) (132,565)

Deemed dividend - - (19,424)

Preferred stock accretion (41) - (802)

Net loss attributable to

common stockholders $(9,736) $ (7,731) $(152,791)

Net loss attributable to

common stockholders per

common share - basic and

diluted $ (10.21) $(0.34)

Weighted-average common

shares outstanding -

basic and diluted 953,959 22,412,689

See accompanying notes to consolidated financial statements

Table 2

Amicus Therapeutics, Inc.

Reconciliation of GAAP to non-GAAP Measures for the Statement of Operations Information for Three Months Ended March 31, 2008

(Unaudited)

(In thousands, except share and per share amounts) <
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... DUBLIN , May 27, 2015 ... addition of Jain PharmaBiotech,s new report "Neuroprotection ... offering. This report describes the role ... and injuries of the nervous system as well ... because many of the underlying mechanisms of damage ...
(Date:5/28/2015)... 2015 Celsion Corporation (the "Company") (NASDAQ: ... from two institutional healthcare investors to purchase an aggregate ... in an at-the-market registered direct offering and a concurrent ... The Company entered into a definitive purchase agreement ... to sell an aggregate of 3,000,000 shares of its ...
(Date:5/28/2015)... DryLet, LLC a biotechnology company providing ... animal waste reduction, bioremediation, wastewater treatment, aquaculture and ... plants and restaurant kitchen settings, announced today it ... 3-5 in Des Moines, Iowa. , ManureMagicâ„¢ was ... Journal article because of its industry-leading qualities and ...
(Date:5/28/2015)... NORTH BRUNSWICK, N.J. , May 28, 2015 ... that PDS0101, a cancer immunotherapy treatment targeting HPV-16, ... patients.  Currently, pre-cervical cancer is ... could offer a simple and effective non-surgical alternative. ... body,s defense mechanisms (T-cells) to recognize, target, and ...
Breaking Biology Technology:Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2
... YORK , Feb. 10 Intellect ... company focused on development of disease-modifying therapeutic agents for ... significant shareholders (the "Interested Shareholders") have agreed in principle ... the Company in its efforts to restructure its balance ...
... YORK , Feb. 10 DuPont (NYSE: ... he expects the DuPont Agriculture & Nutrition segment to grow sales ... across the seed, crop protection, and nutrition and health businesses.   ... is paying off," Borel said at the Goldman Sachs 14th Annual ...
... Additional AeroLEF patents granted in Europe , China ... Feb. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... additional patents in the US for AeroLEF(R), the Company,s proprietary, ... the treatment of moderate to severe acute pain. US patent ...
Cached Biology Technology:Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 2Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 3Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 4DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion 2DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion 3DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion 4DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion 5YM BioSciences granted two US patents for AeroLEF(R) 2YM BioSciences granted two US patents for AeroLEF(R) 3YM BioSciences granted two US patents for AeroLEF(R) 4
(Date:5/5/2015)... May 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, reminds investors and media ... Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held ... The three-day conference is organized into a ... in is themed Global Fraud: Where is the Trust ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... Cell DNA is a news aggregator that compiles life ... them online, and in a daily email digest format, free ... digests, readers can comment on, or tweet their favorite news ... subscribe to receive daily news direct to their email in-box ...
... Powdery mildew is a fungus that infects both crop ... pathogens cause immense crop loss. Despite decades of intense research, ... hyphae to invade the host,s epidermal cells. A European research ... University of Zurich, now published a study in Science ...
... November 2010 The Aeras Global TB Vaccine Foundation ... Foreign Affairs has renewed its funding to Aeras with ... years (2011-2014) to further its efforts to develop new ... This expression of support represents a ...
Cached Biology News:Fertility or powdery mildew resistance? 2Fertility or powdery mildew resistance? 3Aeras awarded €11.7 million ($16 million) grant from Dutch government 2
... PGF2α) is a metabolite of the ... monkeys and humans. 8-iso PGF2α is ... peroxidation. In both humans and monkeys, ... to metabolites having 2 or 4 ...
kismet (dK-20)...
...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: